Columbus, OH (PRWEB) July 27, 2014
The Institute of Safe Medication Practices (ISMP) Found that the number of serious adverse events such as Xarelto bleeding side-effects reported after the use of the Xarelto blood thinner has now out numbered the complaints filed for its competitor Pradaxa, notes Wright & Schulte LLC. Additionally, outpatient prescriptions for Xarelto increased to nearly 1 million prescriptions per quarter while Pradaxa has steadily declined since peaking in early 2012, the ISMP noted in its latest issue of QuarterWatch Report, which monitors and analyzes serious adverse drug events reported to the U.S. Food & Drug Administration (FDA). As the usage of Xarelto increases in the United States, Reuters reported that the first Xarelto bleeding lawsuits are being filed against Bayer AG, the Germany-based company which manufacturers Xarelto. Multidistrict litigation for Pradaxa is currently underway in the U.S. District Court, Southern District of Illinois where 2,481 lawsuits are pending, as of July 15. The Pradaxa bleeding lawsuits are filed on behalf of patients who suffered serious bleeding allegedly from taking the blood thinner. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)
[ismp.org/quarterwatch/pdfs/2013Q1.pdf, May 7, 2014]
July-15-2014.pdf, July 15, 2014]
suit-idUSKBN0EP0HW20140614, June 14, 2014]
The attorneys at Wright & Schulte continue to speak with men and women who have suffered serious side effects from Xarelto side-effects and continues to monitor Xarelto Bleeding lawsuits awaiting litigation. The firm is also representing clients in Pradaxa lawsuits currently pending litigation (MDL 2385). If you believe you have experienced bleeding due to Xarelto contact Wright & Schulte LLD for a free Xarelto lawsuit legal evaluation by calling 1-800-395-0795 or you can visit http://www.yourlegalhelp.com.
In the first quarter of 2013, ISMP found 680 serious adverse event reports associated with rivaroxaban, the generic name for Xarelto, compared to 528 complaints for dabigatran, the generic name for Pradaxa. The ISMP suggests that the trend is mostly due to doctors changing prescriptions for their patients from Pradaxa to Xarelto. In previously QuarterWatch reports, the ISMP said Pradaxa had been the main focus of safety concerns primarily due to the bleeding risks associated with the medication. The t ISMP states that newly published data shows that Pradaxa bleeding risks could be reduced if the FDA would consider two therapeutic options available to health care providers in Europe and Canada. According to the ISMP, one option is to prescribe a lower, 110 mg twice daily dose of Pradaxa, the other option is a new laboratory monitoring test capable of identifying patients at highest risk for serious bleeding.
[ismp.org/quarterwatch/pdfs/2013Q1.pdf, May 7, 2014]
[ismp.org/NEWSLETTERS/acutecare/showarticle.aspx?id=71, February 13, 2014]
Xarelto and Pradaxa are both newer prescription blood thinners compared to warfarin, a blood thinner approved by the FDA in 1954 and marketed under the brand names of Coumadin and Jantoven. Pradaxa was approved by the FDA in 2010 to reduce the risk of stroke in people with atrial fibrillation not caused by a heart valve problem. Xarelto was initially approved by the FDA in July 2011 to reduce deep vein thrombosis and pulmonary embolism in patients who had knee or hip replacement surgery. Xarelto use was expanded in November 2011 to reduce stroke and blood clot risks in patients with atrial fibrillation (irregular heart rhythms). Xarelto received FDA approval again in November 2013 to treat deep vein thrombosis. According to Dr. Ellis Unger, a director in the FDA’s Center for Drug Evaluation and Research, there is no antidote for oral anticoagulants, such as Xarelto and Pradaxa, if significant bleeding should occur in patients taking the blood thinners. In contrast, Dr. Unger said that vitamin K is a reversal agent for people taking warfarin.
[fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654.htm, November 2, 2012]
[fda.gov/Drugs/NewsEvents/ucm405148.htm, July 17, 2014]
Xarelto Lawsuit Purportedly Due To Subdural Hemorrhage
According to court records a Florida woman filed a Xarelto side effects lawsuit in June that alleges her husband died after suffering a subdural hemorrhage. According to the Xarelto lawsuit, the woman’s husband was prescribed Xarelto in January 2012 to treat atrial fibrillation and suffered the subdural hemorrhage in June 23, 2013. He was hospitalized and underwent a medical procedure in an attempt to stop the bleeding. The Xarelto complaint said he died five days later. The complaint purports that the defendants, Janssen Research & Development and Bayer, concealed their knowledge to consumers, the general public and the medical community that Xarelto allegedly causes life-threatening irreversible bleeds. The Xarelto lawsuit further purports that the defendants did not warn or advise how to intervene and stabilize a patient should a bleed occur. (Case 9:14cv80831)
Pradaxa Lawsuit Settlement Of $650 million to settle approximately 4,000 Pradaxa lawsuits
In May 2014, Pradaxa manufacturer, Boehringer Ingelheim, based in Ingelheim, Germany, announced that it would pay $650 million to settle approximately 4,000 Pradaxa lawsuits pending in state and federal courts around the United States. The Pradaxa lawsuits were filed on behalf of plaintiffs who allege they suffered bleeding side-effects after taking the medication. Reuters reported that the compensation each plaintiff receives will be based on the nature and severity of the alleged injury.
[reuters.com/article/2014/05/28/us-boehringer-lawsuit-idUSKBN0E81BL20140528?feedType=RSS, May 28, 2014]
[ca.finance.yahoo.com/news/boehringer-ingelheim-announces-comprehensive-settlement-120000411.html, May 28, 2014]
About Wright & Schulte LLC
Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America’s legal system should work for the people. Every day, the attorneys of Wright & Schulte LLC stand up for the rights of people who have been injured or wronged and fight tirelessly to ensure that even the world’s most powerful corporations take responsibility for their actions. If you or your loved one suffered serious internal bleeding or other related complications as a result of using Xarelto or Pradaxa, contact the law firm for a free, no-obligation legal consultation. If you’re looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today through yourlegalhelp.com or by calling 1-800-399-0795.